Biogen moves the goal posts

  • Eisai and Biogen posted promising data for BAN2401 that lifted its stock and had the pharma trade publications talking breakthrough.
  • But there is a lot of controversy swirling around the study.
  • It seems that Biogen may have moved the goal posts to gain more favorable data endpoints.
  • It’s not about patients, it’s about the stock price and getting investors on board.

Continue reading